bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.07.23.740409

Image-based Disease-wide Association Study via Self-supervised Learning links Abdominal MRI Features to 158 Diseases

Abstract

Medical images contain rich phenotypic information that is often not fully captured by manual clinical assessment. Here, we present a systematic framework for extracting such information and conducting image-based disease-wide association studies (iDWAS) using self-supervised learning (SSL). We applied this framework to abdominal MRI data from the UK Biobank and evaluated associations between MRI-derived features and 562 diseases. Features were learned using a VICReg-based SSL model and tested for disease associations using logistic regression models. We identified 158 diseases that were significantly associated with the MRI-derived features, including the ones which are not directly linked to abdominal anatomy. Focusing on Metabolic dysfunction-associated steatohepatitis (MASH), we showed that the MRI-derived features captured disease-relevant information and separated MASH cases from controls better than established biomarkers such as PDFF and Iron-cT1. These findings highlight the ability of SSL to uncover clinically meaningful signals from routine imaging data. The proposed framework is broadly applicable to other imaging datasets and modalities, enabling more systematic approaches to incidental and early disease detection. The trained model and analysis pipeline are publicly available at https://github.com/srm2022/iDWAS. BackgroundMedical images, often analyzed manually by clinicians, contain valuable information that may not be fully captured by the human eye. Machine Learning (ML) has demonstrated significant potential in extracting this information, allowing us to enhance our understanding of underlying pathologies. We present a systematic framework for extracting such information and performing image-based disease-wide association studies (iDWAS) using self-supervised learning. We then applied the framework to abdominal Magnetic Resonance Imaging (MRI) from UK Biobank (UKB) and investigated the associations between MRI-derived features and 562 diseases. Finally, we delved deeper into the observed associations for Metabolic dysfunction-associated steatohepatitis (MASH), a prevalent yet underdiagnosed condition with a high unmet need for non-invasive diagnostic tools. MethodsWe extracted features from MRI images using VICReg-based self-supervised learning and modeled the associations of the extracted features with 562 diseases using logistic regression. Using the likelihood ratio (LR) test, we then assessed how much additional variance can be explained by the MRI-derived features relative to the variance explained by a null model including only common confounders such as age, gender, and BMI. ResultsOf these 562 diseases, we identified 158 diseases to be significantly associated with the MRI-derived features. While many of them (e.g. MASH) are known to primarily emerge in the abdomen, others (e.g. neuropsychiatric diseases) are not. Taking MASH as a use-case and adjusting for MASH-specific confounding, we then showed that our MRI-derived features captured additional MASH-relevant information compared to standard MRI-derived biomarkers of liver health such as proton density fat fraction (PDFF) and iron-corrected T1 (Iron-cT1). The trained SSL model and analysis pipeline are available at https://github.com/srm2022/iDWAS. ConclusionsOur results illustrate (1) how MRIs from one organ of the body can inform about the diseases primarily rooted in other organs of the body, reflecting patients overall health status, and (2) how SSL can extract more information relevant for specific diseases compared to current state-of-the-art biomarkers. Our framework can be applied to other MRI datasets as well as other imaging modalities with minimal adjustment, providing opportunities for the development of more systematic approaches to incidental diagnosing, i.e. (early) detection of diseases falling outside the scope of the original imaging procedure.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Mousavi, S., Arora, J., Agarwal, R., Fischer, A., Mueller, S., Ding, Z., de Jong, J., Yuan, K.. 2026-07-28. Image-based Disease-wide Association Study via Self-supervised Learning links Abdominal MRI Features to 158 Diseases. https://doi.org/10.64898/2026.07.23.740409

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Heterogeneous Graph Contrastive Learning for Drug-Gene-Disease Motif Prediction

Drug repurposing and target discovery offer critical strategies for advancing therapeutic development by uncovering the potential biological pathways and novel associations among drugs, genes, and diseases. However, experimental discovery remains expensive and time-consuming, which limits the scalability of large-scale studies. In addition, existing computational approaches often struggle to effectively integrate heterogeneous biomedical data, capture the complex higher-order topological signatures of biological interactomes, and generalize to unseen entities. Here, we present HANAMI (Heterogeneous grAph coNtrastive leArning for drug-gene-disease Motif predIction), a multi-view deep graph learning framework designed to model complex interactions among drugs, genes, and diseases. HANAMI integrates diverse heterogeneous biomedical knowledge, including chemical structures, genomic sequences, and clinical phenotypes, and leverages relation-aware topology encoding, structure-aware aggregation, and contrastive learning to enable accurate motif prediction with biological context from the network. Systematic evaluation on benchmark datasets shows that HANAMI achieves up to 6% improvements over existing state-of-the-art methods in predicting drug-gene-disease motifs. The framework further demonstrates strong inductive generalization, maintaining an [~]18% performance advantage in zero-shot settings involving previously unseen entities. Beyond predictive performance, HANAMI effectively prioritizes drug-disease relationships investigated in Phase II or III trials while identifying candidate genes that suggest plausible mechanistic links. Together, HANAMI provides a computational framework for interpreting complex biomedical interactions, offering a scalable foundation to accelerate drug repurposing and therapeutic innovation.

bioinformatics↗

PTMExplorer: A Multi-Dimensional Integrative Visualization Platform for Protein Post-Translational Modification Function and Structure

Deciphering the functions of post-translational modifications (PTMs) is a critical bridge connecting large-scale modification proteomics data to mechanistic studies. However, most existing tools for visualizing PTM omics data are limited to site catalogs or single-dimensional feature displays. They lack the capability to simultaneously map user-derived differential modification sites onto multi-dimensional contexts, including protein three-dimensional (3D) structure, evolutionary conservation, functional sites, and disease associations. This limitation makes it difficult for researchers to rapidly assess the biological importance of candidate sites from among a vast number of differentially modified sites. Here, we present PTMExplorer, an interactive platform for the multi-dimensional visualization of protein PTMs. PTMExplorer comprises three core modules: PTM Inspector, built upon ProtVista, provides a multi-track, sequence-feature integrated view incorporating intrinsically disordered region (IDR) prediction (via flDPnn), surface accessibility calculation (via FreeSASA), and UniProt functional annotations; PTM 3D Locator, leveraging the Nightingale/Mol* engine, anchors modification sites onto AlphaFold/Protein Data Bank (PDB) 3D structures through residue mapping via PDBe-SIFTS; and PTM Overview, utilizing the R circlize package, presents a panoramic polar circos plot illustrating modification distribution and inter-group differential regulation. Additionally, three major disease-associated modification databases (PTMD, qPTM, and PhosCancer) are integrated as PTM-Disease Nexus, enabling co-localization comparison between user-defined differential sites and reported disease-related sites. PTMExplorer currently supports eight model organisms, accepts user-uploaded differential analysis results, and provides multi-dimensional annotations and various visualization options (https://www.bioladder.cn/PTMExplorer/). Using a multi-omics dataset from hepatocellular carcinoma (18 patients, 9 modification types) as a case study, we demonstrate the practical utility of PTMExplorer in screening potential biomarkers, revealing multi-modification coordination mechanisms, and distinguishing between absolute and relative quantification patterns.

bioinformatics↗

Integrative analysis of the MDM2 promoter switch and cellular lineage plasticity in colorectal cancer: a contrast between the autonomous-proliferation type (CIN/CMS2) and the environment-adaptive type (MSI/gastric metaplasia)

Background: Biomarkers that stratify colorectal cancer (CRC) by therapeutic responsiveness and are measurable directly in biopsy specimens remain insufficiently established. We investigated whether usage of the dual MDM2 promoters (P1/P2) acts as a molecular switch separating two diametrically opposed CRC phenotypes: a chromosomal instability type and an environment adaptive type (microsatellite instability/serrated pathway with gastric metaplasia). Methods: Sixty three organoid samples from 22 patients with CRC were classified morphologically by deep learning (VGG16) and molecularly by an MDM2 Splicing Index derived from expression arrays. The P1 and P2 signatures (gene sets characterizing P1 and P2dominant samples) were externally validated in TCGA-COAD/READ (n = 624) and GSE39582 (n = 536), 1,160 cases in total, and therapeutic implications were tested in public cell line panels (GDSC2, DepMap) and in 65 lines of an independent patient derived CRC organoid biobank. Results: Deep learning morphological classification reached 98.5% test accuracy (64/65), and morphology corresponded to P1/P2 isoform usage: Type1 (compact glandular) morphology predominated in P1 dominant samples (median Type1 fraction 0.826 versus 0.444) and non Type1 (cystic mucinous) morphology in P2 dominant samples (AUC 0.79). Both signatures differed across the four consensus molecular subtypes , and the P2 signature was higher in mismatch repair deficient (microsatellite-unstable) tumors. Promoter usage quantified directly (P2_index) was higher in TP53 wild type tumors , consistent with P2 being p53-inducible. TP53 wild type cell lines were more sensitive to the MDM2 inhibitor Nutlin 3a and were more dependent on MDM2 in the DepMap CRISPR screen ; among 198 GDSC2 drugs, Nutlin 3a correlated most strongly with the P2 score. In the independent biobank, TP53 wild type lines (17) were more sensitive to nutlin-3 than mutant lines (48) (median log(IC50) 1.386 versus 4.283). Conclusions: MDM2 promoter choice (P1/P2) co-varies with the lineage identity of cancer cells and with the secretory, mucin rich character of the tumor tissue, consistent with a molecular-switch role alongside p53 suppression. The MDM2 P1/P2 ratio, measurable by RT qPCR or targeted NGS, is a candidate molecular-classification and therapeutic-stratification biomarker corresponding robustly to CMS, MSI, and TP53 mutation status.

bioinformatics↗